Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review

被引：12

作者：

Oliveira, M. A. L. ^{[1
]}

Chellini, P. R. ^{[2
]}

Amorim, T. L. ^{[1
]}

机构：

[1] Univ Fed Juiz de Fora, Chem Dept, BR-36036330 Juiz De Fora, MG, Brazil

[2] Univ Fed Juiz de Fora, Fac Farm, BR-36036330 Juiz De Fora, MG, Brazil

来源：

ANALYTICAL METHODS | 2018年 / 10卷 / 10期

基金：

巴西圣保罗研究基金会;

关键词：

CAPILLARY-ZONE-ELECTROPHORESIS; SPECTROPHOTOMETRIC DETERMINATION; MULTIVARIATE CALIBRATION; TABLETS; DRUGS; OPTIMIZATION; HYDROCHLORIDE; TUBERCULOSIS; VALIDATION; SEPARATION;

D O I：

10.1039/c7ay02686b

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

According to the World Health Organization, rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride are the first-line drugs used to treat tuberculosis - an infectious disease caused by Mycobacterium tuberculosis. Since 2010, tuberculosis has been treated with a fixed-dose combination containing the four drugs in only one tablet, called 4-FDC, which has simplified the treatment, minimized prescription errors and increased patients' adherence to their treatment regime. Within this context, the present review aims to show the evolution of different analytical methods that have been applied to simultaneous 4-FDC content determination in pharmaceutical formulations, such as high performance liquid chromatography, ultrahigh performance liquid chromatography, thin layer chromatography and capillary electrophoresis as separation techniques and molecular spectroscopic techniques associated with chemometric approaches, such as UV, Raman, Fourier transform infrared and near infrared.

引用

页码：1103 / 1116

页数：14

共 37 条

[1]

[Anonymous], 2016, GLOB TUB REP

[2]

[Anonymous], 2010, BRAZ BRAZ PHARM

[3]

[Anonymous], 2016, J FOOD PHARM SCI

[4]

[Anonymous], 2013, USP36 NF31 US PHARM

[5]

[Anonymous], 2012, Asian J Pharm Sci

[6]

[Anonymous], 2009, The Complete Drug Reference, Martindale

[7] Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs [J].

Arbex, Marcos Abdo ;

Lima Varella, Marilia de Castro ;

de Siqueira, Helio Ribeiro ;

Fiuza de Mello, Fernando Augusto .

JORNAL BRASILEIRO DE PNEUMOLOGIA, 2010, 36 (05) :626-640

[8]

Ashokraj Y, 2005, INT J TUBERC LUNG D, V9, P791

[9] Visible spectrophotometric and first-derivative UV spectrophotometric determination of rifampicin and isoniazid in pharmaceutical preparations [J].

Benetton, SA ;

Kedor-Hackmann, ERM ;

Santoro, MIRM ;

Borges, VM .

TALANTA, 1998, 47 (03) :639-643

[10]

Brazil. Ministry of Health. Secretary of Health Surveillance, 2011, GUID TUB CONTR BRAZ

← 1 2 3 4 →